Amgen Inc. (AMGN) Insider Trading

Last 12 months

Insiders sold $29.3M and bought nothing on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. EVP, Operations Esteban Santos sold $20.8M on Feb 26, 41% of their stake, outside a plan. The last open-market buy by an executive or director was in Aug 2015.

Net open-market

−$29.3M

0 buys · 9 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 6

executives and directors

Last open-market buy

Aug 2015

Aug 19, 2015

Get an email when AMGN's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Aug 11 – 13	Rachna Khosla SVP, Business Development	SoldNo plan 2 parts	3,252	$414.06 average	$1.35M	34%	Form 4
Aug 6	Derek Miller SVP, Human Resources	SoldNo plan 2 parts	3,890	$402.54 average	$1.57M	24%	Form 4
Aug 6	Nancy A. Grygiel SVP & CCO	SoldNo plan 2 parts	2,970	$402.16 average	$1.19M	29%	Form 4
May 4	Nancy A. Grygiel SVP & CCO	SoldNo plan	1,237	$323.73	$400k	15%	Form 4
Feb 26	Esteban Santos EVP, Operations	SoldNo plan 2 parts	54,792	$379.12 average	$20.8M	41%	Form 4
Feb 19	Matthew C. Busch VP, Finance & CAO	SoldNo plan	1,000	$375.79	$376k	23%	Form 4
Nov 20, 2025	Nancy A. Grygiel SVP & CCO	SoldNo plan 2 parts	3,139	$337.26 average	$1.06M	30%	Form 4
Nov 12, 2025	Rachna Khosla SVP, Business Development	SoldNo plan	890	$336.24	$299k	11%	Form 4
Nov 12, 2025	Murdo Gordon EVP, Global Commercial Ops	SoldNo plan	6,879	$336.83	$2.32M	14%	Form 4
Aug 20, 2025	Nancy A. Grygiel SVP & CCO	SoldNo plan	1,267	$296.99	$376k	15%	Form 4
Jun 5, 2025	Rachna Khosla SVP, Business Development	SoldNo plan	1,500	$289.68	$435k	16%	Form 4
May 2, 2025	Matthew C. Busch VP, Finance & CAO	SoldNo plan	1,000	$279.69	$280k	20%	Form 4
Feb 19, 2025 – Feb 21, 2025	David M Reese EVP & Chief Technology Officer	SoldNo plan 2 parts	33,936	$301.56 average	$10.2M	48%	Form 4
Feb 19, 2025	Esteban Santos EVP, Operations	SoldNo plan	8,711	$292.84	$2.55M	11%	Form 4
Feb 18, 2025 – Feb 19, 2025	Derek Miller SVP, Human Resources	SoldNo plan 2 parts	2,024	$293.45 average	$594k	19%	Form 4
Feb 11, 2025	Murdo Gordon EVP, Global Commercial Ops	SoldNo plan	8,771	$294.79	$2.59M	17%	Form 4
Feb 7, 2025	Jonathan P Graham EVP & Gen. Counsel & Secy.	SoldNo plan	25,045	$293.12	$7.34M	46%	Form 4
Feb 5, 2025	Nancy A. Grygiel SVP & CCO	SoldNo plan	1,589	$304.47	$484k	18%	Form 4

Aug 11 – 13No plan
Rachna Khosla
SVP, Business Development · sold 3,252 at avg $414.06
$1.35M
34% of stake
Aug 6No plan
Derek Miller
SVP, Human Resources · sold 3,890 at avg $402.54
$1.57M
24% of stake
Aug 6No plan
Nancy A. Grygiel
SVP & CCO · sold 2,970 at avg $402.16
$1.19M
29% of stake
May 4No plan
Nancy A. Grygiel
SVP & CCO · sold 1,237 at $323.73
$400k
15% of stake
Feb 26No plan
Esteban Santos
EVP, Operations · sold 54,792 at avg $379.12
$20.8M
41% of stake
Feb 19No plan
Matthew C. Busch
VP, Finance & CAO · sold 1,000 at $375.79
$376k
23% of stake
Nov 20, 2025No plan
Nancy A. Grygiel
SVP & CCO · sold 3,139 at avg $337.26
$1.06M
30% of stake
Nov 12, 2025No plan
Rachna Khosla
SVP, Business Development · sold 890 at $336.24
$299k
11% of stake
Nov 12, 2025No plan
Murdo Gordon
EVP, Global Commercial Ops · sold 6,879 at $336.83
$2.32M
14% of stake
Aug 20, 2025No plan
Nancy A. Grygiel
SVP & CCO · sold 1,267 at $296.99
$376k
15% of stake
Jun 5, 2025No plan
Rachna Khosla
SVP, Business Development · sold 1,500 at $289.68
$435k
16% of stake
May 2, 2025No plan
Matthew C. Busch
VP, Finance & CAO · sold 1,000 at $279.69
$280k
20% of stake
Feb 19, 2025 – Feb 21, 2025No plan
David M Reese
EVP & Chief Technology Officer · sold 33,936 at avg $301.56
$10.2M
48% of stake
Feb 19, 2025No plan
Esteban Santos
EVP, Operations · sold 8,711 at $292.84
$2.55M
11% of stake
Feb 18, 2025 – Feb 19, 2025No plan
Derek Miller
SVP, Human Resources · sold 2,024 at avg $293.45
$594k
19% of stake
Feb 11, 2025No plan
Murdo Gordon
EVP, Global Commercial Ops · sold 8,771 at $294.79
$2.59M
17% of stake
Feb 7, 2025No plan
Jonathan P Graham
EVP & Gen. Counsel & Secy. · sold 25,045 at $293.12
$7.34M
46% of stake
Feb 5, 2025No plan
Nancy A. Grygiel
SVP & CCO · sold 1,589 at $304.47
$484k
18% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch AMGN, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Biological Products, (No Diagnostic Substances)

GILDGilead Sciences Inc.

BIIBBiogen Inc.

ABTAbbott Laboratories

BMYBristol-Myers Squibb Company

UPCUniverse Pharmaceuticals Inc.

TEVATeva Pharmaceutical Industries Ltd

REGNRegeneron Pharmaceuticals, Inc.

VTRSViatris Inc.

Spot a number that looks wrong? Check it in AMGN's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing AMGN

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.